TABLE 2.
Growth Factor and Cytokine Studies with Past or Current NIAID Support
| Growth factor | Indicationa | Referenceb |
|---|---|---|
|
| ||
| Neupogen (G-CSF, filgrastim)c | H-ARS (neutropenia) | (126) |
| Neulasta (PEG-G-CSF, pegfilgrastim)c | H-ARS (neutropenia) | (127) |
| Nplatec (TPO receptor agonist, romiplostim) | H-ARS (thrombocytopenia) | (71) |
| BBT-059 (PEG-IL-11)c | H-ARS | (80) |
| BBT-007 (PEG-GM-CSF)c | H-ARS | (80) |
| BBT-015 (PEG-G-CSF)c | H-ARS | (80) |
| FGF-Pc | GI-ARS | (65) |
| Bivalent-G-CSF | H-ARS | (128) |
| EGFc | H-ARS | (55) |
| CDX-301 (FMS-like tyrosine kinase-3 ligand, Flt3L) | H-ARS | (15) |
| Human growth hormone (HGH) | H-ARS | (129) |
| Insulin-like growth factor 1 (IGF-1) | CRI | (130) |
| Interleukin-7 (IL-7) | H-ARS | (131) |
| Vascular endothelial growth factor (VEGF) | H-ARS | (132) |
| Platelet-derived growth factor (PDGF) | H-ARS | (133) |
| Keratinocyte growth factor (KGF, Palifermin) | H-ARS, GI-ARS, lung-DEARE | (121) |
| Stem cell factor (SCF) | H-ARS | (15) |
| Neumega (IL-11, Oprelvekin) | H-ARS, GI-ARS | (134) |
| Epogen [epoetin alfa (erythropoietin)] | H-ARS | (123) |
| Basic fibroblast growth factor (bFGF or FGF2)c | H-ARS | (63) |
| R-spondin 1 (WNT signaling) | GI-ARS | (135) |
| Mozobil™ (Plerixafor; stem cell mobilization factor)d | H-ARS, skin | (136) |
| PLX-R18 (placenta-derived cell therapy)d | H-ARS | (137) |
| PEG-TPOmd (pegylated thrombopoietin mimetic peptide) | H-ARS (thrombocytopenia) | (138) |
| PBI-1402 (hematopoietic growth stimulant)d | H-ARS | (139) |
| dmPGE (dimethyl prostaglandin E analog)d | H-ARS | (140) |
| Forteo® (parathyroid hormone)d | H-ARS | (141) |
| 5-Androstenediol (5-AED, estrogen steroid hormone)d | H-ARS | (142) |
a
Hematopoietic (H), gastrointestinal (GI), delayed effect of acute radiation exposure (DEARE), cutaneous radiation injury (CRI).
b
Reference may not reflect NIAID funding.
c
Presentation at the meeting.
d
Product that complements/mimics a growth factor or cytokine.